Business
Interim results for the six months to 30 June 2025
Interim results for the six months to 30 June 2025.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\n\n \n\n\n\nArecor Therapeutics plc\n(\"Arecor\", the \"Company\" or the \"Group\")\n \nInterim results for the six months to 30 June 2025\n \nCambridge, UK, 25 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, reports its unaudited interim results for the six months ended 30 June 2025.\nIn-period operational highlights\n• Portfolio - Diabetes (AT278 / AT247)\n• In vitro modelling in automated insulin delivery (AID) pump systems with insulin pump device companies for AT247 and AT278 generating positive results\n• Extended IP portfolio in major territories\n• Portfolio - Obesity (Oral GLP-1 receptor agonist)\n• Positive in-vitro progress\n• Data on track to be delivered in 2H 2025 to inform next development steps\n• Platform technology, Arestat®\n• Three new formulation development collaborations signed with total pre-license revenue of over £1 million\n• Healthy pipeline of future partnerships and licensing opportunities\n• Expanded IP protection in major territories\n• Non-core operations\n• Sale of inventory and rights to non-Ogluo Tetris products for £0.5m, in May 2025, with orderly cessation of Tetris by end 2025\nPost period-end\n• Positive FDA feedback on Phase 2 clinical study design for ultra-concentrated and ultra-rapid acting insulin, AT278, in combination with an AID system\n• Co-development deal signed with US insulin pump device company, Sequel Med Tech, LLC (\"Sequel\") for Phase 2-enabling activities for AT278. Work already commenced - see separate announcement HERE.\n• Sale of royalty and technology access fee streams for up to $11 million via royalty financing agreement with Ligand Pharmaceuticals Inc (\"Ligand\"); Arecor to receive $7 million upfront - see separate announcement HERE.\n• Extends cash runway to 1H 2027\n• Established new Scientific Advisory Board of world leading experts in oral drug delivery\n \nFinancial highlights (unaudited)\n• Revenue £2.0 million (1H 2024: £2.0 million)\n•...